Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the hiv reverse transcriptase inhibitor tenofovir, in HIV-infected adults

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 5, 2014, Pages 1362-1369

  Markowitz, Martin ^a   Zolopa, Andrew ^b   Squires, Kathleen ^c   Ruane, Peter ^d   Coakley, Dion ^e   Kearney, Brian ^f   Zhong, Lijie ^f   Wulfsohn, Michael ^f   Miller, Michael D ^f   Lee, William A ^f  

^a ROCKEFELLER UNIVERSITY   (United States)

^b STANFORD UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Light Source Medical   (United States)

^e Hyperion Therapeutics Inc   (United States)

^f GILEAD SCIENCES   (United States)

Author keywords

Antiretroviral therapy; NRTIs; Nucleotide reverse transcriptase inhibitors

Indexed keywords

AMYLASE; CREATININE; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GS-7340; PRODRUG; RNA DIRECTED DNA POLYMERASE;

ADULT; AGED; AMYLASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLATULENCE; GINGIVA BLEEDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; INSOMNIA; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RNA VIRUS; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; ADOLESCENT; ANALOGS AND DERIVATIVES; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; HIV INFECTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; PLASMA; VIROLOGY; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; AREA UNDER CURVE; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; PLASMA; PRODRUGS; YOUNG ADULT;

EID: 84898478011     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt532     Document Type: Article

References (19)

1. Schapiro JM, Winters MA, Vierra M et al. Lymph node human immunodeficiency virus RNA levels and resistance mutations in patients receiving high-dose saquinavir. J Infect Dis 1998; 177: 477-80.
2. Yukl SA, Gianella S, Sinclair E et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010; 202: 1553-61.
3. Furtado MR, Callaway DS, Phair JP et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999; 340: 1614-22.
4. Zhang L, Ramratnam B, Tenner-Racz K et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340: 1605-13.
5. Ramratnam B, Mittler JE, Zhang L et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000; 6: 82-5.
6. Satake A, Itoh K, Shimmoto M et al. Distribution of lysosomal protective protein in human tissues. Biochem Biophys Res Commun 1994; 205: 38-43.
7. Birkus G,Wang R, Liu X et al. Cathepsin A is a major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother 2007; 51: 1-7.
8. Cooper RD, Wiebe N, Smith N et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51: 496-505.
9. Gallant JE, Parish MA, Keruly JC et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40: 1194-8.
10. Scherzer R, Estrella M, Li Y et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26: 867-75.
11. LeeWA, He G-X, Eisenberg E et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 2005; 49: 1898-906.
12. Louie M, Hogan C, Hurley A et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS 2003; 17: 1151-6.
13. Polis MA, Sidorov A, Yoder C et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 2001; 358: 1760-5.
14. Mittler J, Essunger P, Yuen GJ et al. Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother 2001; 45: 1438-43.
15. Van Rompay KK, Cherrington JM, Marthas ML et al. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother 1996; 40: 2586-91.
16. Barditch-Crovo P, Deeks SG, Collier A et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45: 2733-9.
17. Ho DD, Neuman AU, Perelson AS et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-6.
18. Ruane P, Dejesus E, Berger D et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide (TAF) as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr 2013; 63: 449-55.
19. Zolopa A, Ortiz R, Sax P et al. Comparative study of tenofovir alafenamide vs tenofovir disoproxil fumarate, each with elvitegravir, cobicistat, and emtricitabine, for HIV treatment. In: Abstracts of the Twentieth Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, 2013. Abstract 99LB. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.